Position on Biosimilars

BioNJ is pleased that a regulatory pathway for biosimilars was included in the Health Care Reform Act. Our position prior to its inclusion and passage appears below. From its inception, the biotechnology industry has been driven by the application of cutting-edge science and innovative approaches and technologies that has resulted in the discovery, development and… Read the full article